Evidence map›Paper›PMID 34543291›Full record

ArticlePloS one2021

A multi-component, community-based strategy to facilitate COVID-19 vaccine uptake among Latinx populations: From theory to practice.

Carina Marquez, Andrew D Kerkhoff, Jamie Naso, Maria G Contreras, Edgar Castellanos Diaz, Susana Rojas, James Peng, Luis Rubio, Diane Jones, Jon Jacobo and 13 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
10.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. An exploration of COVID-19 vaccination models for newcomer refugees and immigrants in Calgary, Canada.Archives of public health = Archives belges de sante publique · 2024
    Article
  20. Article

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 1 country.

Carina MarquezDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-7622-6562
Andrew D KerkhoffDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.ORCID 0000-0002-5023-6658
Jamie NasoUnidos en Salud, San Francisco, California, United States of America.
Maria G ContrerasUnidos en Salud, San Francisco, California, United States of America.
Edgar Castellanos DiazUnidos en Salud, San Francisco, California, United States of America.
Susana RojasThe San Francisco Latino Task Force-Response to COVID-19, San Francisco, California, United States of America.
James PengDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.
Luis RubioDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.
Diane JonesUnidos en Salud, San Francisco, California, United States of America.
Jon JacoboThe San Francisco Latino Task Force-Response to COVID-19, San Francisco, California, United States of America.
Susy RojasThe San Francisco Latino Task Force-Response to COVID-19, San Francisco, California, United States of America.
Rafael GonzalezSan Francisco Department of Public Health, San Francisco, California, United States of America.
Jonathan D FuchsSan Francisco Department of Public Health, San Francisco, California, United States of America.
Douglas BlackDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.
Salustiano RibeiroBay Area Phlebotomy and Laboratory Services (BayPLS), San Francisco, California, United States of America.
Jen NossokoffBay Area Phlebotomy and Laboratory Services (BayPLS), San Francisco, California, United States of America.ORCID 0000-0002-1550-9315
Valerie Tulier-LaiwaThe San Francisco Latino Task Force-Response to COVID-19, San Francisco, California, United States of America.
Jacqueline MartinezUnidos en Salud, San Francisco, California, United States of America.
Gabriel ChamieDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.
Genay PilarowskiDepartment of Pathology, Stanford University, Stanford, California, United States of America.
Joseph DeRisiChan Zuckerberg Biohub, San Francisco, California, United States of America.
Maya PetersenDivision of Epidemiology and Biostatistics, School of Public Health, University of California, Berkeley, Berkeley, California, United States of America.
Diane V HavlirDivision of HIV, Infectious Diseases and Global Medicine, Zuckerberg San Francisco General Hospital and Trauma Center, University of California San Francisco, San Francisco, California, United States of America.
San Francisco General Hospital · USUnited in Health · USUniversity of California, San Francisco · USBay Area Hospital · USSan Francisco Department of Public Health · USStanford University · USUniversity of California, Berkeley · US

Funding

Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

backgroundCOVID-19 vaccine coverage in the Latinx community depends on delivery systems that overcome barriers such as institutional distrust, misinformation, and access to care. We hypothesized that a community-centered vaccination strategy that included mobilization, vaccination, and "activation" components could successfully reach an underserved Latinx population, utilizing its social networks to boost vaccination coverage.

methodsOur community-academic-public health partnership, "Unidos en Salud," utilized a theory-informed approach to design our "Motivate, Vaccinate, and Activate" COVID-19 vaccination strategy. Our strategy's design was guided by the PRECEDE Model and sought to address and overcome predisposing, enabling, and reinforcing barriers to COVID-19 vaccination faced by Latinx individuals in San Francisco. We evaluated our prototype outdoor, "neighborhood" vaccination program located in a central commercial and transport hub in the Mission District in San Francisco, using the Reach, Effectiveness, Adoption, Implementation and Maintenance (RE-AIM) framework during a 16-week period from February 1, 2021 to May 19, 2021. Programmatic data, city-wide COVID-19 surveillance data, and a survey conducted between May 2, 2021 and May 19, 2021 among 997 vaccinated clients ≥16 years old were used in the evaluation.

resultsThere were 20,792 COVID-19 vaccinations administered at the neighborhood site during the 16-week evaluation period. Vaccine recipients had a median age of 43 (IQR 32-56) years, 53.9% were male and 70.5% were Latinx, 14.1% white, 7.7% Asian, 2.4% Black, and 5.3% other. Latinx vaccinated clients were substantially more likely than non-Latinx clients to have an annual household income of less than $50,000 a year (76.1% vs. 33.5%), be a first-generation immigrant (60.2% vs. 30.1%), not have health insurance (47.3% vs. 16.0%), and not have access to primary care provider (62.4% vs. 36.2%). The most frequently reported reasons for choosing vaccination at the site were its neighborhood location (28.6%), easy and convenient scheduling (26.9%) and recommendation by someone they trusted (18.1%); approximately 99% reported having an overall positive experience, regardless of ethnicity. Notably, 58.3% of clients reported that they were able to get vaccinated earlier because of the neighborhood vaccination site, 98.4% of clients completed both vaccine doses, and 90.7% said that they were more likely to recommend COVID-19 vaccination to family and friends after their experience; these findings did not substantially differ according to ethnicity. There were 40.3% of vaccinated clients who said they still knew at least one unvaccinated person (64.6% knew ≥3). Among clients who received both vaccine doses (n = 729), 91.0% said that after their vaccination experience, they had personally reached out to at least one unvaccinated person they knew (61.6% reached out to ≥3) to recommend getting vaccinated; 83.0% of clients reported that one or more friends, and/or family members got vaccinated as a result of their outreach, including 18.9% who reported 6 or more persons got vaccinated as a result of their influence.

conclusionsA multi-component, "Motivate, Vaccinate, and Activate" community-based strategy addressing barriers to COVID-19 vaccination for the Latinx population reached the intended population, and vaccinated individuals served as ambassadors to recruit other friends and family members to get vaccinated.

Indexed as

Hispanic or LatinoResidence CharacteristicsAdolescentAdultCOVID-19COVID-19 VaccinesEthnicityFemaleGeographyHumansMaleMiddle AgedRacial GroupsSan FranciscoTime FactorsTreatment OutcomeCOVID-19 Vaccines

Identifiers

PMID34543291
PMCPMC8452046
OpenAlexW3201366661

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.